Shopping Cart 0
Cart Subtotal
AED 0

Peptic Ulcers-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Peptic Ulcers-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers-Pipeline Review, H2 2017, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 4, 1 and 8 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peptic Ulcers-Overview

Peptic Ulcers-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Peptic Ulcers-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peptic Ulcers-Companies Involved in Therapeutics Development

Astellas Pharma Inc

Balto Therapeutics

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

Sequella Inc

Sinil Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Peptic Ulcers-Drug Profiles

(lafutidine + irsogladine maleate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(lansoprazole + omeprazole)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6537-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholesteryl glucoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1386-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-206-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KJ-14001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SI-001002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 for Peptic Ulcers and Reflux Esophagitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SQ-109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptic Ulcers-Dormant Projects

Peptic Ulcers-Discontinued Products

Peptic Ulcers-Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca'sPrilosec Patents Upheld By Court

Jun 01, 2007: AstraZeneca'sPrilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Peptic Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Peptic Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peptic Ulcers-Pipeline by Astellas Pharma Inc, H2 2017

Peptic Ulcers-Pipeline by Balto Therapeutics, H2 2017

Peptic Ulcers-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017

Peptic Ulcers-Pipeline by RaQualia Pharma Inc, H2 2017

Peptic Ulcers-Pipeline by Sequella Inc, H2 2017

Peptic Ulcers-Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Peptic Ulcers-Dormant Projects, H2 2017

Peptic Ulcers-Dormant Projects, H2 2017 (Contd..1), H2 2017

Peptic Ulcers-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Astellas Pharma Inc

Balto Therapeutics

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

Sequella Inc

Sinil Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Peptic Ulcers-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers-Pipeline Review, H2 2017, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 4, 1 and 8 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peptic Ulcers-Overview

Peptic Ulcers-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Peptic Ulcers-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peptic Ulcers-Companies Involved in Therapeutics Development

Astellas Pharma Inc

Balto Therapeutics

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

Sequella Inc

Sinil Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Peptic Ulcers-Drug Profiles

(lafutidine + irsogladine maleate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(lansoprazole + omeprazole)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6537-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholesteryl glucoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1386-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-206-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KJ-14001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SI-001002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 for Peptic Ulcers and Reflux Esophagitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SQ-109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptic Ulcers-Dormant Projects

Peptic Ulcers-Discontinued Products

Peptic Ulcers-Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca'sPrilosec Patents Upheld By Court

Jun 01, 2007: AstraZeneca'sPrilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Peptic Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Peptic Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peptic Ulcers-Pipeline by Astellas Pharma Inc, H2 2017

Peptic Ulcers-Pipeline by Balto Therapeutics, H2 2017

Peptic Ulcers-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017

Peptic Ulcers-Pipeline by RaQualia Pharma Inc, H2 2017

Peptic Ulcers-Pipeline by Sequella Inc, H2 2017

Peptic Ulcers-Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Peptic Ulcers-Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Peptic Ulcers-Dormant Projects, H2 2017

Peptic Ulcers-Dormant Projects, H2 2017 (Contd..1), H2 2017

Peptic Ulcers-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Astellas Pharma Inc

Balto Therapeutics

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

Sequella Inc

Sinil Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd